```
on Post (File 146)
***Books in Print (File 470)
***Court Filings (File 793)
***Microcomputer Software Guide Online (File 278)
***Publishers, Distributors & Wholesalers of the U.S. (File 450)
***State Tax Today (File 791)
***Tax Notes Today (File 790)
***Worldwide Tax Daily (File 792)

***New document supplier***
IMED has been changed to INFOTRIE (see HELP OINFOTRI)


>>>Get immediate news with Dialog's First Release
   news service.  First Release updates major newswire
   databases within 15 minutes of transmission over the
   wire.  First Release provides full Dialog searchability
   and full-text features.  To search First Release files in
   OneSearch simply BEGIN FIRST for coverage from Dialog's
   broad spectrum of news wires.

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                  ****

File   1:ERIC  1966-2002/Jun 06
       (c) format only 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
? b 410
       24jun02 08:05:06 User208760 Session D2082.1
            $0.31    0.088 DialUnits File1
     $0.31  Estimated cost File1
     $0.31  Estimated cost this search
     $0.31  Estimated total session cost   0.088 DialUnits

File 410:Chronolog(R)  1981-2002/Jun
       (c) 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
       24jun02 08:05:12 User208760 Session D2082.2
            $0.00    0.070 DialUnits File410
     $0.00  Estimated cost File410
     $0.01  TELNET
     $0.01  Estimated cost this search
     $0.32  Estimated total session cost   0.157 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2002/Jun W3
         (c) 2002 BIOSIS
  File  73:EMBASE  1974-2002/Jun W3
         (c) 2002 Elsevier Science B.V.
*File  73: For information about Explode feature please
see Help News73.
  File 155:MEDLINE(R)  1966-2002/Jun W3
*File 155: Daily alerts are now available. This file has
been reloaded. Accession numbers have changed.
```

File 399:CA SEARCH(R) 1967-2002/UD=13626
(c) 2002 AMERICAN CHEMICAL SOCIETY
*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

```
      Set  Items  Description
      ---  -----  -----------
? s (TAA or tumor(w)associated(w)antigen?) (20n)(PAP or PSMA)
           3992  TAA
        1634581  TUMOR
        2479469  ASSOCIATED
        1480450  ANTIGEN?
          10261  TUMOR(W)ASSOCIATED(W)ANTIGEN?
          22006  PAP
            532  PSMA
      S1       9  (TAA OR TUMOR(W)ASSOCIATED(W)ANTIGEN?) (20N)(PAP OR PSMA)
? rd s1
...completed examining records
      S2       5  RD S1 (unique items)
? t s2/3/all
```

2/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08950302 BIOSIS NO.: 199396101803
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
AUTHOR: Garde Seema V; Sheth Anil R; Porter Arthur T; Pienta Kenneth J
AUTHOR ADDRESS: Inst. Res. Reproduction, Jehangir Merwanji Street, Parel, Bombay 400012**India
JOURNAL: Cancer Letters 70 (3):p159-166 1993
ISSN: 0304-3835
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

06149463 BIOSIS NO.: 000085112615
A COMPARISON OF THREE IMMUNOPEROXIDASE TECHNIQUES FOR ANTIGEN DETECTION IN COLORECTAL CARCINOMA TISSUES
AUTHOR: SHI Z-R; ITZKOWITZ S H; KIM Y S
AUTHOR ADDRESS: GI RES. LAB., VA MED. CENT., 4150 CLEMENT ST., SAN FRANCISCO, CALIF. 94121.
JOURNAL: J HISTOCHEM CYTOCHEM 36 (3). 1988. 317-322. 1988
FULL JOURNAL NAME: Journal of Histochemistry and Cytochemistry
CODEN: JHCYA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

2/3/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

04165976 EMBASE No: 1990048518
Immunohistological demonstration of virus and tumor associated antigens in tissues in experimental and spontaneous bovine leukemia virus (BLV) infection

Reinacher M.; Thurmond M.C.; Onuma M.; Portetelle D.; Picanso J.; Theilen G.H.
Department of Pathology, School of Veterinary Medicine, University of Giessen, Frankfurter Strasse 96, D-6300 Giessen Germany
Veterinary Immunology and Immunopathology (VET. IMMUNOL. IMMUNOPATHOL.) (Netherlands) 1989, 22/3 (223-231)
CODEN: VIIMD ISSN: 0165-2427
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

2/3/4 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06513342 90194688 PMID: 2560854
Immunohistological demonstration of virus and tumor associated antigens in tissues experimental and spontaneous bovine leukemia virus (BLV) infection.
Reinacher M; Thurmond M C; Onuma M; Portetelle D; Picanso J; Theilen G H
Department of Pathology, School of Veterinary Medicine, University of Giessen, F.R.G.
Veterinary immunology and immunopathology (NETHERLANDS) Oct 1989, 22 (3) p223-31, ISSN 0165-2427 Journal Code: 8002006
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

2/3/5 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06283076 89368522 PMID: 2672236
Diagnostic and therapeutic utility of monoclonal antibodies in urologic oncology.
McCarley D L; Weiner R S
Department of Medicine, Gainesville VA Medical Center.
Seminars in surgical oncology (UNITED STATES) 1989, 5 (4) p293-301, ISSN 8756-0437 Journal Code: 8503713
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
? t s2/7/all

2/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08950302 BIOSIS NO.: 199396101803
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
AUTHOR: Garde Seema V; Sheth Anil R; Porter Arthur T; Pienta Kenneth J
AUTHOR ADDRESS: Inst. Res. Reproduction, Jehangir Merwanji Street, Parel, Bombay 400012**India
JOURNAL: Cancer Letters 70 (3):p159-166 1993
ISSN: 0304-3835
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Prostatic inhibin peptide (PIP), consisting of 94 amino-acid residues is synthesized and secreted by the prostate gland. Previous

studies on immunohistochemical localization of PIP in primary prostatic tumor and their metastasis, have documented the value of this peptide as a tumor marker for diagnosis of prostate cancer (PCa). The present study was undertaken to compare the expression of PIP with that of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in androgen independent human PCa cell lines (PC-3, DU-145 and TSU-Prl) by immunoperoxidase technique. The results of the study indicated that the staining for PIP was more intense than that of PSA and PAP. The PSA staining was either weakly positive (PC-3) or totally absent (TSU-Prl and DU-145) while PAP staining was intense in PC-3 and moderate in the other two human cell lines. The intense staining observed for PIP in all of the androgen independent cell lines suggests that the synthesis and secretion of PIP is not primarily dependent on androgens. Furthermore, expression of these markers in Dunning rat cultured adenocarcinoma cell lines and tumors were studied. Positive staining for all three human **tumor associated antigens** (PIP, PSA and **PAP**) cross-reacting with the Dunning rat PCa cell lines and the tumors, suggest the suitability of this model for preclinical screening of various therapeutic agents.

2/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06149463 BIOSIS NO.: 000085112615
A COMPARISON OF THREE IMMUNOPEROXIDASE TECHNIQUES FOR ANTIGEN DETECTION IN COLORECTAL CARCINOMA TISSUES
AUTHOR: SHI Z-R; ITZKOWITZ S H; KIM Y S
AUTHOR ADDRESS: GI RES. LAB., VA MED. CENT., 4150 CLEMENT ST., SAN FRANCISCO, CALIF. 94121.
JOURNAL: J HISTOCHEM CYTOCHEM 36 (3). 1988. 317-322. 1988
FULL JOURNAL NAME: Journal of Histochemistry and Cytochemistry
CODEN: JHCYA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: We compared the streptavidin-peroxidase conjugate (SP) method of immunoperoxidase histochemistry to the unlabeled antibody (PAP) and avidin-biotin-peroxidase complex (ABC) techniques in human colorectal carcinoma tissues stained with a monoclonal antibody for expression of carcinoembryonic antigen. Compared to the ABC and PAP methods, the SP method produced stronger stainig intensity and very low background staining. This was true when other antibody isotypes, other antibody species, other organs, and another **tumor-associated antigen** were used. Moreover, the SP procedure time could be reduced to one third that of the ABC or **PAP** methods without compromising accuracy, and the SP reagent is stable for several months. The chemical nature of the streptavidin molecule accounts, in large part, for the advantages of the SP method.

2/7/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

04165976 EMBASE No: 1990048518
Immunohistological demonstration of virus and tumor associated antigens in tissues in experimental and spontaneous bovine leukemia virus (BLV) infection
Reinacher M.; Thurmond M.C.; Onuma M.; Portetelle D.; Picanso J.; Theilen G.H.
Department of Pathology, School of Veterinary Medicine, University of Giessen, Frankfurter Strasse 96, D-6300 Giessen Germany

Veterinary Immunology and Immunopathology (VET. IMMUNOL. IMMUNOPATHOL.) (Netherlands) 1989, 22/3 (223-231)
CODEN: VIIMD ISSN: 0165-2427
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Expression of bovine leukemia virus (BLV) antigens in vivo has not been shown. After BLV infection, however, production of antibodies directed toward BLV proteins (e.g. gp51) can be easily demonstrated. Thus, production of BLV proteins has to take place somewhere in infected cattle. Tissues and organs of experimentally infected cattle were fixed in acetone and embedded in paraffin. Monoclonal antibodies directed to gp51 were used to demonstrate BLV expression immunohistologically by the peroxidase-antiperoxidase (**PAP**) method. The same samples were also used to demonstrate a **tumor associated antigen** (**TAA**) employing a monoclonal antibody. Our results indicate that very few cells, found in the intestinal mucosa, produce gp51 in vivo. The expression of TAA, however, increases significantly shortly after infection with BLV and remains high throughout life.

2/7/4 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06513342 90194688 PMID: 2560854
Immunohistological demonstration of virus and tumor associated antigens in tissues experimental and spontaneous bovine leukemia virus (BLV) infection.
Reinacher M; Thurmond M C; Onuma M; Portetelle D; Picanso J; Theilen G H
Department of Pathology, School of Veterinary Medicine, University of Giessen, F.R.G.
Veterinary immunology and immunopathology (NETHERLANDS) Oct 1989, 22 (3) p223-31, ISSN 0165-2427 Journal Code: 8002006
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Expression of bovine leukemia virus (BLV) antigens in vivo has not been shown. After BLV infection, however, production of antibodies directed towards BLV proteins (e.g. gp51) can be easily demonstrated. Thus, production of BLV proteins has to take place somewhere in infected cattle. Tissues and organs of experimentally infected cattle were fixed in acetone and embedded in paraffin. Monoclonal antibodies directed to gp51 were used to demonstrate BLV expression immunohistologically by the peroxidase-antiperoxidase (**PAP**) method. The same samples were also used to demonstrate a **tumor associated antigen** (**TAA**) employing a monoclonal antibody. Our results indicate that very few cells, found in the intestinal mucosa, produce gp51 in vivo. The expression of TAA, however, increases significantly shortly after infection with BLV and remains high throughout life.
Record Date Created: 19900417

2/7/5 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06283076 89368522 PMID: 2672236
Diagnostic and therapeutic utility of monoclonal antibodies in urologic oncology.
McCarley D L; Weiner R S
Department of Medicine, Gainesville VA Medical Center.
Seminars in surgical oncology (UNITED STATES) 1989, 5 (4) p293-301, ISSN 8756-0437 Journal Code: 8503713
Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Remarkable advances in the treatment of urologic malignancies have recently been made. Monoclonal antibodies selective for a variety of normal and malignant urologic tissues have been useful in defining normal antigens and tumor-associated antigens and have potential as diagnostic and immunotherapeutic agents. In renal cancer, monoclonal antibodies can define serum markers, radiolabel tumor xenografts, and assist in specific tissue diagnosis. Additionally, there is potential for these antibodies either alone or as conjugates to localize and kill tumors. Monoclonal antibodies to bladder cancer associated antigens are able to demonstrate differential antigen expression on superficial versus invasive tumors, to refine urinary cytologic diagnosis of bladder cancer, and to predict invasive recurrence of superficial cancer. Monoclonal antibodies have localized bladder tumor xenografts and can inhibit tumor growth when conjugated to radioisotopes or toxins. In prostate cancer monoclonal antibodies to prostate antigens are not usually tumor specific. Monoclonal antibodies to prostate antigen (PA) and prostatic acid phosphatase (PAP) are able to localize prostate cancer metastases. Chemotherapy-conjugated anti-**PAP** monoclonal antibodies have demonstrable inhibition on human prostate cancer xenografted tumor growth. Monoclonal antibodies have defined normal and **tumor-associated antigens** in urologic cancers and are expected to be useful in immunodiagnosis and cancer therapy in the near future. (63 Refs.)
Record Date Created: 19890926

```
? s (TAA or tumor(w)associated(w)antigen?) and (PSMA)
          3992  TAA
       1634581  TUMOR
       2479469  ASSOCIATED
       1480450  ANTIGEN?
         10261  TUMOR(W)ASSOCIATED(W)ANTIGEN?
           532  PSMA
      S3    10  (TAA OR TUMOR(W)ASSOCIATED(W)ANTIGEN?) AND (PSMA)
? rd s3
...completed examining records
      S4     6  RD S3 (unique items)
? t s4/7/all

 4/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.
```

13709647 BIOSIS NO.: 200200338468
Immunotherapy of cancer through expression of truncated tumor or **tumor-associated antigen**.
AUTHOR: Mincheff Milcho S(a); Loukinov Dmitri I; Zoubak Serguei
AUTHOR ADDRESS: (a)Rockville, MD**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1258 (2):pNo Pagination May 14, 2002
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: DNA constructs for truncated forms of cancer-specific or cancer associated antigens are included in plasmid or viral expression vectors. The rationale to use constructs for truncated and not for full-size molecules is to eliminate side effects (toxicity, signal transduction etc.) arising from expressed proteins and/or, in cases where such molecules are expressed on the membrane, secreted, or released in the extracellular environment, to prevent formation of antibodies against them. The extracellular portion of the human prostate specific membrane

specific antigen (XC-**PSMA**) has been cloned. Patients were treated either by injection of DNA coding for XC-**PSMA** in a mammalian expression vector under the CMV promoter or/and by a replication-defective adenoviral vector (Ad5)hat contains an expression cassette for the XC-**PSMA**. In a third method dendritic cells are isolated from a patient and are treated by exposure to the plasmid or adenovirus used in the previous two treatments. The dendritic cells are then injected into the patient. In some patients, the progression of metastatic prostate cancer is retarded or stopped.

4/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11202591 EMBASE No: 2001217258

In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile

Mincheff M.; Altankova I.; Zoubak S.; Tchakarov S.; Botev C.; Petrov S.; Krusteva E.; Kurteva G.; Kurtev P.; Dimitrov V.; Ilieva M.; Georgiev G.; Lissitchkov T.; Chernozemski I.; Meryman H.T.
M. Mincheff, Biomedical Research Institute, 12111 Parklawn Drive, Rockville, MD 20852 United States
AUTHOR EMAIL: mcamsm@gwu.edu

Critical Reviews in Oncology/Hematology (CRIT. REV. ONCOL. HEMATOL.) (Ireland) 2001, 39/1-2 (125-132)
CODEN: CCRHE ISSN: 1040-8428
PUBLISHER ITEM IDENTIFIER: S1040842801001111
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32

In order to provoke an immune response, a tumor vaccine should not only maximize antigen-specific signals, but should also provide the necessary 'co-stimulatory' environment. One approach is to genetically manipulate tumor cells to either secrete lymphokines (GM-CSF, IL-12, IL-15) or express membrane bound molecules (CD80, CD86). Furthermore, patient dendritic cells can be loaded with **tumor-associated antigens** or peptides derived from them and used for immunotherapy. Genetic modification of dendritic cells can also lead to presentation of **tumor-associated antigens**. Transfection of dendritic cells with DNA encoding for such antigens can be done in vitro, but transfection efficiency has been uniformly low. Alternatively, dendritic cells can also be modulated directly in vivo either by 'naked' DNA immunization or by injecting replication-deficient viral vectors that carry the tumor specific DNA. Naked DNA immunization offers several potential advantages over viral mediated transduction. Among these are the inexpensive production and the inherent safety of plasmid vectors, as well as the lack of immune responses against the carrier. The use of viral vectors enhances the immunogenicity of the vaccine due to the adjuvant properties of some of the viral products. Recent studies have suggested that the best strategy for achieving an intense immune response may be priming with naked DNA followed by boosting with a viral vector. We have successfully completed a phase I and phase II clinical trials on immunotherapy of prostate cancer using naked DNA and adenoviral immunizations against the prostate-specific membrane antigen (**PSMA**) and phase I clinical trial on colorectal cancer using naked DNA immunization against the carcinoembryonic antigen (CEA). The vaccination was tolerated well and no side effects have been observed so far. The therapy has proven to be effective in a number of patients treated solely by immunizations. The success of the treatment clearly depends on the stage of the disease proving to be most efficient in patients with minimal disease or no metastases. A panel of changes in the

phenotype of peripheral blood lymphocytes and the expression of intra-T-cell lymphokines seems to correlate with clinical improvement.

4/7/3 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

07222228 EMBASE No: 1998088223
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
Zhang S.; Zhang H.S.; Reuter V.E.; Slovin S.F.; Scher H.I.; Livingston P.O.
P.O. Livingston, Department of Medicine, Memorial Sloan-Kettering Can. Center, 1275 York Avenue, New York, NY 10021 United States
Clinical Cancer Research (CLIN. CANC. RES.) (United States) 1998, 4/2 (295-302)
CODEN: CCREF ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 38

Defining the expression of **tumor-associated antigens** on primary and metastatic prostate cancer is the crucial first step in selecting appropriate targets for immune attack. In this study, the distribution of the **tumor- associated antigens** GM2, Tn, sTn, Thompson-Friedenreich antigen (TF), Globo H, Le(y), MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, carcinoembryonic antigen, beta chain of human chorionic gonadotropin (hCGbeta), HER2/neu, **PSMA**, and KSA on primary and metastatic prostate cancer and 16 types of normal tissues was compared by immunohistochemistry, using a panel of well- characterized monoclonal antibodies. Our results show that GM2, KSA, and MUC2 were strongly expressed on 8 or 9 of 9 metastatic prostate cancer biopsy specimens and, with **PSMA**, hCGbeta, TF, Tn, and sTn, on 8 or more of 11 primary prostate cancer specimens. Tn, MUC1, and **PSMA** were expressed on 4-6 of 9 metastatic specimens. The remaining antigens were expressed on no more than three of nine metastatic specimens. Normal tissues were also tested with all antibodies. With regard to the eight antigens most widely expressed on prostate cancers, **PSMA** was not expressed significantly on any of the normal tissues except prostate epithelium. Tn, sTn, hCGbeta, and MUC2 were detected on up to 3 of 10 types of normal epithelia. GM2, TF, MUC1, and KSA were more broadly distributed on normal epithelia, all primarily at the secretory borders. STn, KSA, and hCGbeta were also detected in the testis, and GM2 was expressed on gray matter of brain. From the 30 antigens that we have screened, this study provides the basis for selecting GM2, TF, Tn, sTn, hCGbeta, MUC1, MUC2, KSA, and **PSMA** as target antigens for specific immunotherapy of prostate cancer.

4/7/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134276498 CA: 134(20)276498m PATENT
Engineering of replication selective adenoviruses with tumor-associated antigen promoter for use in cancer therapy
INVENTOR(AUTHOR): Molnar-kimber, Katherine; Toyoizumi, Takane
LOCATION: USA
ASSIGNEE: The Trustees of the University of Pennsylvania
PATENT: PCT International ; WO 200123004 A1 DATE: 20010405
APPLICATION: WO 2000US27212 (20001002) *US PV157224 (19990930)
PAGES: 56 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A; A01N-063/00B; C12Q-001/68B; C12N-005/00B; C12N-015/63B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG ; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA203002 Biochemical Genetics

CA201XXX Pharmacology

CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY

IDENTIFIERS: adenovirus vector replication selective cancer therapy, tumor assocd antigen promoter adenovirus vector

DESCRIPTORS:

Pituitary hormones...
.alpha.-subunit, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Proteins,specific or class...
apoptosis-regulating, vector encoding; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Transcription factors...
c-myb, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Lung,neoplasm...
carcinoma, non-small cell, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Carcinoembryonic antigen...
CEA, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Proteins,specific or class...
cell cycle-assocd., promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Neoplasm...
cell, expressing tumor-assocd. antigen, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Uterus,neoplasm...
cervix, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Intestine,neoplasm...
colorectal adenocarcinoma, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Artery,disease...
coronary, restenosis, therapy; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Transcription factors...
Egr-1, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Virus vectors...
encoding therapeutic peptide; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Drug delivery systems... Gene therapy... Genetic engineering...

engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Mucins...
episialins, MUC-1/DF-3, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Proteins,specific or class...
erb1 or erb2, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Gene,microbial...
E1A, deactivation of promoter of; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Gene,microbial...
E1B, deactivation of promoter of; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Transcription factors...
E2F, E2F-1, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Gene,microbial...
E4, deactivation of promoter of; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Proteins,specific or class...
gene H19, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Liver,neoplasm...
hepatoma, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Cell proliferation...
hyper-, mutant adenovirus replication assocd. with; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Mutation...
in E1A, E1B, and E4 promoter; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Phosphoproteins...
l-plastins (leukocyte plastins), promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Mesothelium...
mesothelioma, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Adenoviridae...
mutant; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Head... Mammary gland... Neck,anatomical... Prostate gland...
neoplasm, promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Gene...
oncogene, vector contg.; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Proteins,specific or class...
probasins, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter

for use in cancer therapy
Disease,animal...
proliferative, intimal, therapy; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Glial fibrillary acidic protein... Gonadotropins... neu(receptor)...
Prostate-specific antigen... Thyroglobulin... .alpha.-Fetoproteins...
promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Brain,neoplasm... Carcinoma... Kidney,neoplasm... Leukemia... Lymphoma...
Ovary,neoplasm... Pancreas,neoplasm... Sarcoma... Skin,neoplasm...
Stomach,neoplasm... Thyroid gland,neoplasm...
promoter specific to; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antigens...
prostate specific membrane antigen (PSMA), promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Hypertension...
pulmonary, therapy; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antibodies...
recombinant, vector encoding; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
DNA formation...
replication, adenoviral, in cancer or hyperproliferative cells; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Transgene...
suicide; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Proteins,specific or class...
survivin, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Chemotherapy... Immunostimulation... Radiotherapy...
target cell further treated by; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Promoter(genetic element)...
tumor or tissue specific, from tumor-assocd. antigen gene; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Gene,animal...
tumor suppressor, vector contg.; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antigens...
tumor-assocd., promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antigens...
vaccine, vector encoding; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antiviral agents...
vector comprises gene for; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Antisense RNA...
vector contg.; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

Cytokines... Enzymes,biological studies... Immunomodulators... Ribozymes...
vector encoding; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
Human adenovirus 5...
vector; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
CAS REGISTRY NUMBERS:
120178-12-3 catalytic subunit, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
9001-51-8 II, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
9014-08-8 neuron-specific, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
9002-10-2 promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
67763-97-7 P3 and P4, promoter, specific to tumor expressing; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy
332957-23-0 332957-24-1 332957-25-2 332957-26-3 332957-27-4 332957-28-5 332957-29-6 332957-30-9 332957-31-0 332957-32-1
unclaimed sequence; engineering of replication selective adenoviruses with tumor-assocd. antigen promoter for use in cancer therapy

4/7/5 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133054574 CA: 133(5)54574y PATENT
Recombinant vectors expressing multiple costimulatory molecules, host cell infection, and uses in immunogenic applications
INVENTOR(AUTHOR): Schlom, Jeffrey; Hodge, James; Panicali, Dennis
LOCATION: USA
ASSIGNEE: United States Dept. of Health and Human Services; Therion Biologics Corporation
PATENT: PCT International ; WO 200034494 A1 DATE: 20000615
APPLICATION: WO 99US26866 (19991112) *US PV111582 (19981209)
PAGES: 188 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/86A; C12N-005/10B; C07K-014/705B; A61K-039/00B; A61K-035/76B; C12Q-001/00B
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA203005 Biochemical Genetics
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY
CA213XXX Mammalian Biochemistry
CA215XXX Immunochemistry
IDENTIFIERS: vector costimulatory mol antigen epitope T cell activation therapy
DESCRIPTORS:
Bone marrow... Lymph node... Muscle... Neoplasm... Skin... Spleen...
antigen presenting cell derived from, expression host; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Animal tissue... Bacteria(Eubacteria)... Fungi... Neoplasm... Parasite...

Protozoa... Virus... Yeast...
antigene specific to; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Chlamydia... Haemophilus influenzae... Legionella... Listeria...
Mycobacterium... Salmonella... Streptococcus...
bacterial antigen derived from; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
bcr-c-abl, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
BRCA1, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
BRCA2, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal... Gene,animal...
c-erbB2, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
CA-125, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Antigens...
CD70; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Carcinoembryonic antigen...
CEA(6D), with Asp at the position 576; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Neoplasm...
cell line derived from, expression host; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
C1; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
early, of SV40 virus; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Simian virus 40...
early promoter of; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
EWS, fli-1, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Antigen-presenting cell... B cell(lymphocyte)... Dendritic cell...
Fibroblast... Macrophage... Monocyte...
expression host; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
Flt-3L; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
CD40(antigen)... Tumor necrosis factors...
for dendritic cell treatment; recombinant vectors expressing multiple

costimulatory mols., host cell infection, and uses in immunogenic applications

Interferons...
.gamma., vaccine enhancement by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...
GP-100, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Gene,microbial...
gpt, as genetic marker; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Human herpesvirus 5...
human, immediate early promoter of; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Cell adhesion molecules...
ICAM-1 (intercellular adhesion mol. 1); recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Promoter(genetic element)...
immediate early, I, of human CMV; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Promoter(genetic element)...
I3; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Gene,microbial...
lacZ, as genetic marker; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...
MAGE-1, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...
MAGE-3, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Promoter(genetic element)...
major late, of adenovirus; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Adenoviridae...
major late promoter of; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...
MART-1, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Aspergillus... Candida... Cryptosporidium... Histoplasma capsulatum... Leishmania... Nocardia... Plasmodium(malarial genus)... Pneumocystis carinii... Toxoplasma gondii...
microbial antigen derived from; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...
MUC-1, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

Proteins,specific or class...

MUC-2, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
NY-ESO-1, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Cell activation... Cell proliferation...
of T lymphocyte; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Antigens...
OX-40L; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
PAX3, fkhr, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Blood...
peripheral, antigen presenting cell derived from, expression host; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Eukaryote(Eukaryotae)... Poxviridae... Prokaryote... Rous sarcoma virus... Virus...
promoter of; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
PSMA, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Plasmid vectors...
pT5049; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Plasmid vectors...
pT5064; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
ras, tumor- or tissue specific antigen encoded by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Carcinoembryonic antigen... CD40(antigen)... CD4-positive T cell... CD59(antigen)... CD80(antigen)... CD86(antigen)... CD8-positive T cell... Chemokines... Cytokines... Cytotoxicity... Drug delivery systems... Drug screening... Epitopes... Gene therapy... Genetic markers... Genetic vectors ... LFA-3(antigen)... Mitogens... Peptide library... Plasmid vectors... Prostate-specific antigen... Recombination... Vaccines... Virus vectors...
recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
sE/L; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
TAA, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
TAG72, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,microbial...
tk, as genetic marker; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,animal...
TP53, tumor- or tissue specific antigen encoded by; recombinant vectors

expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
TRP-1 (tyrosinase-related protein 1), as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Proteins,specific or class...
TRP-2 (tyrosinase-related protein 2), as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,microbial...
uidA, as genetic marker; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Interleukin 2...
vaccine enhancement by; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Gene,microbial...
vaccinia K1L host range, as genetic marker; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Cell adhesion molecules...
VCAM-1; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Cytomegalovirus... Hepatitis A virus... Hepatitis B virus... Hepatitis C virus... Hepatitis delta virus... Hepatitis E virus... Hepatitis virus... Herpesviridae... Human herpesvirus... Human immunodeficiency virus 2... Influenza virus... Lentivirus... Orthomyxovirus... Papillomavirus...
viral antigen derived from; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Alphavirus... Avipoxvirus... Canarypox virus... Capripoxvirus... Fowlpox virus... Herpesviridae... Iridovirus... Orthopoxvirus... Picornaviridae... Retroviridae... Suipoxvirus... Vaccinia virus...
viral vector based on; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Antigens...
17-1A, as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
30K; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Antigens...
4-1BBL; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
40K; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
Promoter(genetic element)...
7.5K; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
CAS REGISTRY NUMBERS:
129437-45-2 144449-86-5 154330-44-6 154330-45-7 154652-68-3
156250-91-8 156251-11-5 156761-76-1 160040-04-0 160212-35-1
160214-78-8 160215-60-1 160790-21-6 160983-12-0 162558-12-5
162558-13-6 166188-11-0 167319-68-8 168635-85-6 169896-35-9
170173-06-5 170294-35-6 174881-39-1 175614-17-2 177333-26-5
180695-71-0 186351-24-6 187968-34-9 188191-49-3 188606-63-5
189170-01-2 197146-50-2 198274-43-0 275793-89-0 275793-90-3 amino acid sequence; Recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

9002-10-2 as tumor- or tissue specific antigen; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
276687-08-2 unclaimed protein sequence; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications
132326-74-0 138831-86-4 145253-17-4 276236-70-5 unclaimed sequence; recombinant vectors expressing multiple costimulatory mols., host cell infection, and uses in immunogenic applications

4/7/6 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130166887 CA: 130(13)166887x JOURNAL
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens
AUTHOR(S): Zhang, Shengle; Zhang, Helen S.; Cordon-Cardo, Carlos; Ragupathi, Govindaswami; Livingston, Philip O.
LOCATION: Departments of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
JOURNAL: Clin. Cancer Res. DATE: 1998 VOLUME: 4 NUMBER: 11 PAGES: 2669-2676 CODEN: CCREF4 ISSN: 1078-0432 LANGUAGE: English PUBLISHER: American Association for Cancer Research
SECTION:
CA215002 Immunochemistry
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: tumor protein antigen target immunotherapy
DESCRIPTORS:
Antigens...
KSA; selection of tumor protein antigens as targets for immunotherapy
Prostatic tumors...
metastasis; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC2; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC3; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC4; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC5AC; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC5B; selection of tumor protein antigens as targets for immunotherapy
Mucins...
MUC7; selection of tumor protein antigens as targets for immunotherapy
Metastasis(tumor)...
prostatic; selection of tumor protein antigens as targets for immunotherapy
Tumor-associated antigen...
protein; selection of tumor protein antigens as targets for immunotherapy
Antigens...
PSMA (prostate-specific membrane antigen); selection of tumor protein antigens as targets for immunotherapy
B cell lymphoma... Breast tumors... Carcinoembryonic antigen... Colon tumors... Endometrial tumors... Gastric tumors... Immunotherapy... Lung tumors... Melanoma... MUC1 mucin... neu(receptor)... Neuroblastoma... Ovarian tumors... Pancreatic tumors... Sarcoma... Small-cell carcinoma(lung)...
selection of tumor protein antigens as targets for immunotherapy
CAS REGISTRY NUMBERS:

9002-61-3 .beta.; selection of tumor protein antigens as targets for immunotherapy

```
? s (TAA or tumor(w)associated(W)antigen) (20n)(prostate)
            3992  TAA
         1634581  TUMOR
         2479469  ASSOCIATED
         1067283  ANTIGEN
            5492  TUMOR(W)ASSOCIATED(W)ANTIGEN
          174010  PROSTATE
      S5      45  (TAA OR TUMOR(W)ASSOCIATED(W)ANTIGEN) (20N)(PROSTATE)
? rd s5
...completed examining records
      S6      27  RD S5 (unique items)
? t s6/3/all

 6/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13378575   BIOSIS NO.: 200200007396
P504S: A new molecular marker for the detection of prostate carcinoma.
AUTHOR: Jiang Zhong(a); Woda Bruce A; Rock Kenneth L; Xu Yingdan; Savas Lou
  ; Khan Ashraf; Pihan German; Cai Feng; Babcook John S; Rathanaswami
  Palaniswami; Reed Steven G; Xu Jiangchun; Fanger Gary R
AUTHOR ADDRESS: (a)Department of Pathology, University of Massachusetts
  Medical School, 55 Lake Avenue, Worcester, MA, 01655**USA E-Mail:
  jiangz@ummhc.org
JOURNAL: American Journal of Surgical Pathology  25 (11):p1397-1404
November, 2001
MEDIUM: print
ISSN: 0147-5185
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 6/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13086344   BIOSIS NO.: 200100293493
CML66, a novel tumor antigen, is the target of a humoral immune response
  associated with remission of chronic myelocytic leukemia after donor
  lymphocyte infusion.
AUTHOR: Yang Xiao-Feng(a); Wu Catherine J(a); McLaughlin Stephen(a);
  Chillemi Antoinette(a); Wang Kathy S(a); Dranoff Glenn(a); Ritz Jerome(a)
AUTHOR ADDRESS: (a)Center for Hematologic Oncology, Dana-Farber Cancer
  Institute, Harvard Medical School, Boston, MA**USA
JOURNAL: Blood  96 (11 Part 1):p143a November 16, 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of
Hematology  San Francisco, California, USA  December 01-05, 2000
SPONSOR: American Society of Hematology
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English


 6/3/3     (Item 3 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12836799   BIOSIS NO.: 200100043948
```

A novel human **prostate tumor associated antigen** identified by differential gene expression analysis.
AUTHOR: Bright R K(a); Zang J S; Kimchi E T; Adams J W(a); Shridhar V; Smith D I
AUTHOR ADDRESS: (a)Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, 97213**USA
JOURNAL: FASEB Journal 14 (6):pA1006 April 20, 2000
MEDIUM: print
CONFERENCE/MEETING: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society Seattle, Washington, USA May 12-16, 2000
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12637833 BIOSIS NO.: 200000391335
Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof.
AUTHOR: Bosslet Klaus(a); Pfleiderer Peter; Seemann Gerhard
AUTHOR ADDRESS: (a)Marburg**Germany
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1231 (5):pNo pagination Feb. 29, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

6/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12550574 BIOSIS NO.: 200000304076
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: Implications for clinical genetic vaccine development.
AUTHOR: Charles Linda G; Xie Yilin C; Restifo Nicholas P; Roessler Blake; Sanda Martin G
AUTHOR ADDRESS: (a)Department of Surgery/Urology, University of Michigan School of Medicine, 1500 East Medical Center Drive, 2916 Taubman Center, Ann Arbor, MI, 48109-0330**USA
JOURNAL: World Journal of Urology 18 (2):p136-142 April, 2000
MEDIUM: print
ISSN: 0724-4983
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11449135 BIOSIS NO.: 199800230467
Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.

AUTHOR: Hinkle George H(a); Burgers John K; Olsen John O; Williams Bonnie S ; Lamatrice Renita A; Barth Rolf F; Rogers Barbara; Maguire Robert T
AUTHOR ADDRESS: (a)Dep. Radiol., Ohio State Univ. Med. Cent., Room 203D, Doan Hall, 410 West Tenth Ave., Columbus, **USA
JOURNAL: Journal of Nuclear Medicine 39 (4):p650-652 April, 1998
ISSN: 0161-5505
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10760677 BIOSIS NO.: 199799381822
A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.
AUTHOR: Pizza Giancarlo(a); De Vinci Caterina; Cuzzocrea Diego; Menniti Domenico; Aiello Ernesto; Maver Paolo; Corrado Giuseppe; Romagnoli Piero; Dragoni Ennio; Loconte Giuseppe; Riolo Umberto; Palareti Aldopaolo; Zucchelli Paolo; Fornarola Vittorio; Viza Dimitri
AUTHOR ADDRESS: (a)Immunodiagnosis Immunotherapy Unit, 1st Div. Urol., Sant'Orsola-Malpighi Hosp., Via P. Palagi 9,**Italy
JOURNAL: Biotherapy (Dordrecht) 9 (1-3):p123-132 1996
ISSN: 0921-299X
RECORD TYPE: Abstract
LANGUAGE: English

6/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10196956 BIOSIS NO.: 199698651874
Modulation of **tumor-associated antigen** expression on human pancreatic and **prostate** carcinoma cells in vitro by alpha- and gamma-interferons.
AUTHOR: Sivinski Connie L; Lindner Daniel J; Borden Ernest C; Tempero Margaret A(a)
AUTHOR ADDRESS: (a)Dep. Intern. Med., University Nebraska Medical Center, 600 South 42nd Street, Omaha, NE 68198**USA
JOURNAL: Journal of Immunotherapy with Emphasis on Tumor Immunology 18 (3):p156-165 1995
ISSN: 1067-5582
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08590772 BIOSIS NO.: 199345008847
Molecular characterization of the 7E11-C5 **prostate tumor-associated antigen**.
AUTHOR: Troyer John K; Feng Qi; Beckett Mary Lou; Morningstar Michelle M; Wright George L Jr
JOURNAL: Journal of Urology 149 (4 SUPPL.):p333A 1993
CONFERENCE/MEETING: Eighty-eighth Annual Meeting of the AUA (American Urological Association) San Antonio, Texas, USA May 15-20, 1993
ISSN: 0022-5347
RECORD TYPE: Citation

LANGUAGE: English

6/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08286023 BIOSIS NO.: 000043052096
THE INFLUENCE OF ALTERED HEMATOGENOUS FACTORS ON THE SPECIFICITY OF HOST'S ANTITUMOR IMMUNITY
AUTHOR: RAY P; BHATTI R; GADAROWSKI J
AUTHOR ADDRESS: DIV. UROL. COOK COUNTY HOSP., CHICAGO, ILL. 60612.
JOURNAL: 83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, MAY 20-23, 1992. PROC AM ASSOC CANCER RES ANNU MEET 33 (0). 1992. 311. 1992
CODEN: PAMRE
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06450212 BIOSIS NO.: 000037022223
CONCOMITANT PURIFICATION OF PROSTATIC CARCINOMA TUMOR MARKERS PAP AND PSA FROM HUMAN SEMINAL FLUID BY HPLC CHROMATOGRAPHY
AUTHOR: RUSCIANO D; BERARDI A; PACENTI L; TERRANA B
AUTHOR ADDRESS: CELL. BIOL. LAB., RES. CENT., SCLAVO S.P.A., VIA FIORENTINA 1, 53100 SIENA, ITALY.
JOURNAL: SYMPOSIUM ON IN VIVO DIAGNOSIS AND THERAPY OF HUMAN TUMORS WITH MONOCLONAL ANTIBODIES, PART I, NAPLES, ITALY, MARCH 16-19, 1988. NUCL MED BIOL 16 (2). 1989. 177. 1989
CODEN: NMBIE
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06248348 BIOSIS NO.: 000086082530
MONOCLONAL ANTIBODY PR92 WITH RESTRICTED SPECIFICITY FOR **TUMOR-ASSOCIATED ANTIGEN** OF **PROSTATE** AND BREAST CARCINOMA
AUTHOR: KIM Y D; ROBINSON D Y; TOMITA J T
AUTHOR ADDRESS: DIAGNOSTICS DIV., DEP. 90C, ABBOTT LAB., NORTH CHICAGO, ILLINOIS 60064.
JOURNAL: CANCER RES 48 (16). 1988. 4543-4548. 1988
FULL JOURNAL NAME: Cancer Research
CODEN: CNREA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05925586 BIOSIS NO.: 000035016949
PROSTATE AND BREAST **TUMOR-ASSOCIATED ANTIGEN** DEFINED BY MONOCLONAL ANTIBODY PR92

AUTHOR: KIM Y; ROBINSON D; TOMITA J
AUTHOR ADDRESS: ABBOTT LAB., NORTH CHICAGO, ILLINOIS 60064.
JOURNAL: 72ND ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, LAS VEGAS, NEVADA, USA, MAY 1-5, 1988. FASEB (FED AM SOC EXP BIOL) J 2 (5). 1988. ABSTRACT 6812. 1988
CODEN: FAJOE
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05916502 BIOSIS NO.: 000035007865
HELPFUL ADDITION OF **TUMOR ASSOCIATED ANTIGEN** TPA TO IMMUNOCHEMICAL MONITORING OF **PROSTATE** CANCER
AUTHOR: ALLHOFF E; JAKOVIDIS G; FRANZEN W; OETTE K; ENGELKING R; JONAS U
AUTHOR ADDRESS: HANNOVER, FRG.
JOURNAL: EIGHTY-THIRD ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION, BOSTON, MASSACHUSETTS, USA, JUNE 3-7, 1988. J UROL 139 (4 PART 2). 1988. 480A. 1988
CODEN: JOURA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

03972924 BIOSIS NO.: 000076058490
CELL MEDIATED IMMUNITY IN PROSTATIC CANCER AND ITS DIAGNOSTIC RELEVANCY
AUTHOR: ABLIN R J; GUINAN P D; BHATTI R A
AUTHOR ADDRESS: DIV. IMMUNOL., COOK COUNTY HOSP., CHICAGO, ILL. 60612, USA.
JOURNAL: EUR J CANCER CLIN ONCOL 19 (4). 1983. 467-472. 1983
FULL JOURNAL NAME: European Journal of Cancer & Clinical Oncology
CODEN: EJCOD
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

03430352 BIOSIS NO.: 000023003440
RESTRICTED IMMUNOGENICITY OF A **PROSTATE TUMOR ASSOCIATED ANTIGEN**
AUTHOR: WEBB K S; WARE J L; PAULSON D F
AUTHOR ADDRESS: DUKE UNIV. MEDICAL CENT., DURHAM, N.C. 27710.
JOURNAL: 66TH ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, NEW ORLEANS, LA., USA, APRIL 15-23, 1982. FED PROC 41 (3). 1982. ABSTRACT 257. 1982
CODEN: FEPRA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

02902808 BIOSIS NO.: 000069010924
ARMING OF NORMAL LEUKOCYTES WITH SERA FROM PATIENTS WITH ADENO CARCINOMA OF THE PROSTATE
AUTHOR: BHATTI R A; ABLIN R J; CONDOULIS W; GUINAN P D
AUTHOR ADDRESS: DIV. UROL., HEKTOEN INST. MED. RES., COOK CTY. HOSP., CHICAGO, ILL. 60612, USA.
JOURNAL: CANCER RES 39 (9). 1979. 3328-2221. 1979
FULL JOURNAL NAME: Cancer Research
CODEN: CNREA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/18 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

10742873 EMBASE No: 2000223379
Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines
Kawai K.; Tani K.; Asano S.; Akaza H.
Dr. K. Kawai, Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-City Ibaraki 305 Japan
AUTHOR EMAIL: rkawa@md.tsukuba.ac.jp
Molecular Urology (MOL. UROL.) (United States) 2000, 4/2 (43-46)
CODEN: MOURF ISSN: 1091-5362
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 13

6/3/19 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

02416968 EMBASE No: 1983127979
Monoclonal antibodies to different epitopes on a **prostate tumor-associated antigen**. Implications for immunotherapy
Webb K.S.; Ware J.L.; Parks S.F.; et al.
Dep. Surg., Div. Urol., Duke Univ. Med. Cent., Durham, NC 27710 United States
Cancer Immunology Immunotherapy (CANCER IMMUNOL. IMMUNOTHER.) (Germany) 1983, 14/3 (155-166)
CODEN: CIIMD
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

6/3/20 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09781795 98192203 PMID: 9533532
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin S F; Scher H I; Divgi C R; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson S M
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Clinical cancer research : an official journal of the American Association for Cancer Research (UNITED STATES) Mar 1998, 4 (3) p643-51, ISSN 1078-0432 Journal Code: 9502500

Contract/Grant No.: CA05826; CA; NCI; CA09512; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/21 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09143445 97029184 PMID: 8875196
Biomarker expression in prostatic intraepithelial neoplasia.
Myers R B; Grizzle W E
Department of Pathology, University of Alabama at Birmingham 35291-0007, USA.
European urology (SWITZERLAND) 1996, 30 (2) p153-66, ISSN 0302-2838 Journal Code: 7512719
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/22 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132147631 CA: 132(12)147631j PATENT
Tumor-associated antigen peptides and use thereof in anti-tumor vaccines
INVENTOR(AUTHOR): Eisenbach, Lea; Carmon, Lior; Tirosh, Boaz; Bar-Haim, Erez; Paz, Adrian; Fridkin, Matityahu; Fitzer-Attas, Cheryl
LOCATION: Israel
ASSIGNEE: Yeda Research and Development Company Ltd At the Weizmann Institute of Scien; Bio-Technology General Corp.
PATENT: PCT International ; WO 0006723 A1 DATE: 20000210
APPLICATION: WO 99IL417 (19990729) *IL 125608 (19980730)
PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/12A; C07K-014/47B; C07K-014/705B; C12N-009/16B; C12N-009/64B; A61K-038/17B; A61K-038/46B; A61K-038/47B; C12N-015/55B; C12N-015/57B; C12N-005/08B
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/23 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130065224 CA: 130(6)65224y PATENT
Human prostate tumor inducing gene-1, its detection, and methods of preparing various hybridoma cell lines
INVENTOR(AUTHOR): Fisher, Paul B.; Shen, Ruoqian
LOCATION: USA
ASSIGNEE: The Trustees of Columbia University In the City of New York
PATENT: United States ; US 5851764 A DATE: 19981222
APPLICATION: US 371377 (19950111) *US 603804 (19901025) *US 106323 (19930813) *US 225493 (19940411) *US 351888 (19941208)
PAGES: 58 pp., Cont.-in-part of U.S. Ser. No. 351,888. CODEN: USXXAM
LANGUAGE: English CLASS: 324006000; C12Q-001/68A; C07H-021/04B;

G01N-033/00B; C12N-015/00B

6/3/24 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

129329394 CA: 129(25)329394e PATENT
A prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers
INVENTOR(AUTHOR): Laus, Reiner; Ruegg, Curtis L.; Shapero, Michael H.; Yang, Demao
LOCATION: USA
ASSIGNEE: Dendreon Corp.
PATENT: PCT International ; WO 9846769 A1 DATE: 19981022
APPLICATION: WO 98US7232 (19980410) *US 43301 (19970411)
PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/55A; C12N-009/16B; C12N-015/86B; A61K-038/46B DESIGNATED COUNTRIES: AU; CA; JP; MX; NO; NZ; US DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB ; GR; IE; IT; LU; MC; NL; PT; SE

6/3/25 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

128203898 CA: 128(17)203898h JOURNAL
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
AUTHOR(S): Zhang, Shengle; Zhang, Helen S.; Reuter, Victor E.; Slovin, Susan F.; Scher, Howard I.; Livingston, Philip O.
LOCATION: Memorial Sloan-Kettering Cancer Center, Clinical Immunology Service, New York, NY, 10021, USA
JOURNAL: Clin. Cancer Res. DATE: 1998 VOLUME: 4 NUMBER: 2 PAGES: 295-302 CODEN: CCREF4 ISSN: 1078-0432 LANGUAGE: English PUBLISHER: American Association for Cancer Research

6/3/26 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126099307 CA: 126(8)99307k PATENT
Antibodies and prostate antigen-binding probes for treatment and diagnosis of prostate cancer, and production of monoclonal antibodies
INVENTOR(AUTHOR): Bander, Neil H.
LOCATION: USA
ASSIGNEE: Cornell Research Foundation, Inc.
PATENT: PCT International ; WO 9639185 A1 DATE: 19961212
APPLICATION: WO 96US8306 (19960603) *US 463500 (19950605)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B; C12N-005/20B; G01N-033/53B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI DESIGNATED REGIONAL: KE; LS; MW; SD; SZ ; UG; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML

6/3/27 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

120130998 CA: 120(11)130998p DISSERTATION

Characterization of a novel prostate tumor-associated antigen
AUTHOR(S): Lipford, Grayson Bernard
LOCATION: Old Dominion Univ., Norfolk, VA, USA
DATE: 1992 PAGES: 138 pp. CODEN: DABBBA LANGUAGE: English CITATION: Diss. Abstr. Int. B 1993, 53(8), 4020 AVAIL: Univ. Microfilms Int., Order No. DA9230209
? t s6/7/15

6/7/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

03972924 BIOSIS NO.: 000076058490
CELL MEDIATED IMMUNITY IN PROSTATIC CANCER AND ITS DIAGNOSTIC RELEVANCY
AUTHOR: ABLIN R J; GUINAN P D; BHATTI R A
AUTHOR ADDRESS: DIV. IMMUNOL., COOK COUNTY HOSP., CHICAGO, ILL. 60612, USA.
JOURNAL: EUR J CANCER CLIN ONCOL 19 (4). 1983. 467-472. 1983
FULL JOURNAL NAME: European Journal of Cancer & Clinical Oncology
CODEN: EJCOD
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Cell-mediated immunity (CMI) in prostatic cancer patients to presumptively identified prostatic tumor-associated antigens (TAA) was evaluated by tube leukocyte adherence inhibition in 504 patients with and without prostatic cancer. Peripheral blood leukocytes from 210 of 312 (67%) prostatic cancer patients possessed significant reactivity to extracts of malignant prostate. Significant reactivity to malignant prostate was also observed in 89 of 192 (46%) controls comprised of patients with other than carcinoma of the prostate [including 91 patients with benign prostatic hypertrophy of which 46 (51%) possessed significant reactivity to malignant prostate] and healthy adults. With the exception of a significant difference in the reactivity between stage A vs. stage C patients, there was no significant correlation between the level of reactivity to malignant **prostate** and the stage of disease. Had CMI to presumptively identified prostatic **TAA** been employed as an adjunctive diagnostic criterion to detect prostatic cancer, 191 (38%) of the 504 patients in this study would have been incorrectly diagnosed. The results emphasize the critical need in attempting to delineate tumor-directed immunity from possible concomitant sensitization to tissue- and species-specific antigens for the identification, isolation and physicochemical characterization of what previously have been referred to as presumptively or putatively identified prostatic TAA.
?